Formed in 2024 through the merger of Mipharm and Doppel, Domixtar Pharmaceutical is an Italian Contract Development and Manufacturing Organization (CDMO) providing fully integrated solutions for the development, formulation, and production of pharmaceuticals. Its portfolio includes a wide range of liquid, solid, and semi-solid dosage forms, serving leading European and international pharmaceutical companies.
DMX employs around 900 people across four manufacturing sites located in Italy and is expected to generate approximately Euro 170 million in revenues in 2025.
With the support of Azzurra Capital and The Club Dealers, DMX will continue its growth and consolidation path in the European CDMO sector, leveraging its strong industrial base, advanced technological capabilities, and experienced management team to further strengthen its leadership position in pharmaceutical manufacturing.
The deal was supported by BNL, Banco BPM, Crédit Agricole Italia, MPS, UniCredit, Banca IFIS, CDP and Banca Sella.
